The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2021 | Treating MGRS and MGUS with neuropathy
Stefan Knop, MD, University Hospital of Würzburg, Würzburg, Germany, gives an update on the field of treatment of monoclonal gammopathy of renal significance (MGRS) and monoclonal gammopathy of undetermined significance (MGUS). Prof. Knop outlines the pathology of MGUS and MGRS, challenges around diagnosis and treatment approaches for patients with MGRS and MGUS with neuropathy. This interview took place during the 3rd European Society of Hematology How to Diagnose and Treat Multiple Myeloma (ESH MM) 2021 congress.
